<unk> , is a pathological process in the body where the blood starts to coagulate throughout the whole body. This depletes the body of its platelets and<unk>  factors, and there is a paradoxically increased risk of hemorrhage. It occurs in critically ill patients, especially those with Gram-negative sepsis (particularly meningococcal sepsis) and acute promyelocytic leukemia.<unk>  is a complex and highly variable disorder, whose manifestations depend upon the inciting event, the host response and underlying comorbid disease. Additionally, the morbidity and mortality in patients with<unk>  often depends more on the underlying disease and he specific pathophysiology. As such, well-designed studies are obviously difficult to design, and there is therefore little consensus regarding management. The term<unk>  has evolved from the terms ‘consumptive coagulopathy’ and later, ‘defibrination syndrome’. Although most physicians are aware of the hemorrhage that is seen in patients with<unk> , the<unk> ’ in<unk>  actually refers to both hemorrhage and thrombosis. In actuality, the thrombosis, both micro and macro-vascular, with resulting ischemia, contributes more to morbidity and mortality than the hemorrhage. Bick defines<unk>  as ‘a systemic thrombohemorrhagic disorder seen in association with well-defined clinical situations AND laboratory evidence for procoagulant activation, fibrinolytic activation, inhibitor consumption, and evidence of end-organ damage’.
Disseminated intravascular coagulation
Heparin-induced thrombocytopenia
Sticky platelet syndrome
Grey platelet syndrome
Pseudo gray platelet syndrome
Idiopathic thrombocytopenic purpura radiation
Idiopathic thrombocytopenic purpura
Thrombotic thrombocytopenic purpura